Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | GSK | LLY |
|---|---|---|
| Price | $49.74 | $1,187.15 |
| Change today | ▲ 0.05% | ▲ 3.14% |
| Market cap | $99.64B | $1.12T |
| Return, 3 months | -1.8% | +6.4% |
| Return, year to date | +4.1% | +11.0% |
| Return, 1 year | +28.2% | +61.0% |
| P/E (TTM) | 15.9 | 39.9 |
| P/B | 4.3 | 33.0 |
| P/E percentile vs own 5y | 63rd | 5th |
| Dividend yield | 3.57% | 0.54% |
| Revenue growth (YoY, latest qtr) | +5.3% | +47.7% |
| Net profit growth (YoY) | -66.4% | +25.3% |
| Gross margin | 72.7% | 83.4% |
| Operating margin | 20.7% | 49.7% |
| Net margin | 14.5% | 33.5% |
| Return on equity | 29.7% | 102.4% |
| Analyst target vs. price | +40.7% | +15.6% |
| Analyst buy share | 0% | 86% |
| RSI (14) | 50 | 51 |
| 30-day volatility | 25.0% | 26.1% |
| Max drawdown, 1 year | -19.3% | -23.2% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.